Quetzal Therapeutics Launches Phase III Clinical Trial of Oral QTX-2101 for Acute Promyelocytic Leukemia (APL)
CHICAGO, Dec. 02, 2025 (GLOBE NEWSWIRE) — Quetzal Therapeutics, a biopharmaceutical company specializing in developing transformative treatments for rare diseases, announced the initiation of a pivotal Phase III clinical trial of QTX-2101, an investigational oral arsenic trioxide capsule. The trial will evaluate the efficacy, safety, and pharmacokinetics of QTX-2101, as a potential new treatment for acute promyelocytic leukemia (APL), a […]
Quetzal Therapeutics Appoints Todd Smith as Board Member
Quetzal Therapeutics, a newly formed biopharmaceutical company, announced its official launch today with $50 million of committed capital.
Quetzal Therapeutics Debuts with Expert Leadership, High-Impact Pipeline and $50 Million of Committed Capital
Quetzal Therapeutics, a newly formed biopharmaceutical company, announced its official launch today with $50 million of committed capital.